Pediatric NHL is the third most common malignancy in children. These diverse lymphoid cancers include mature B-cell NHL, lymphoblastic lymphoma, anaplastic large cell lymphoma and post-transplant lymphoproliferative disease (PTLD).
Do you wonder why some children with NHL require only several weeks of treatment, while others are treated for 2 years? Or, how staging and classification impact the risk of relapse? Current national trials have incorporated targeted therapies such as brentuximab and crizotinib into standard chemotherapy regimens with the goal of improving survival and decreasing long-term toxicities. We’ll follow six children and teenagers with newly diagnosed NHL through staging, risk classification, and treatment assignment to highlight the different clinical approaches that are required to successfully treat patients with these diverse pediatric cancers.
- Opening Keynote: Secrets Everyone in Health Care Needs to Know (101)
- General Session: International Pediatric Hematology/Oncology Nursing Initiatives: Challenges and Opportunities (102)
- It's All GREEK To Me! The NEPENTHE Trial for Relapsed/Refractory Neuroblastoma; Personalized Molecularly Targeted Treatment (200)
- A Sustainable Community Engagement Program Model to Address Hematopoietic Cell Transplantation Education Needs for Patients with Sickle Cell Disease (201)
- Nursing Management for the Successful Application of the Chimeric Antigen Receptor (CAR) T-Cell Immunotherapy (212)
- Karyn Brundige, MSN CPNP